Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naive patients with Crohn's disease: Results from the EVOLVE Expansion study

被引:0
|
作者
Ferrante, M. [1 ]
Christensen, B. [2 ,3 ]
Bressler, B. [4 ]
Brett, N. [5 ]
Bassel, M. [5 ]
Kamble, P. [6 ]
Adsul, S. [6 ]
Gianchetti, L. [7 ]
Scharl, M. [8 ]
机构
[1] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
[2] Royal Melbourne Hosp, Dept Gastroenterol, Melbourne, Vic, Australia
[3] Univ Melbourne, Dept Med, Melbourne, Vic, Australia
[4] St Pauls Hosp, Vancouver, BC, Canada
[5] Thermo Fisher Sci, PPD, Montreal, PQ, Canada
[6] Takeda Pharmaceut, Cambridge, MA USA
[7] Thermo Fisher Sci, PPD, Philadelphia, PA USA
[8] Univ Zurich, Univ Zurich Hosp, Dept Gastroenterol & Hepatol, Zurich, Switzerland
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
26
引用
收藏
页码:116 / 117
页数:2
相关论文
共 50 条
  • [41] COMPARISON OF REAL-WORLD TREATMENT OUTCOMES WITH INFLIXIMAB VERSUS VEDOLIZUMAB IN BIOLOGIC-NAIVE PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Latremouille-Viau, Dominick
    Burne, Rebecca
    Shi, Sherry
    Adsul, Shashi
    Patel, Haridarshan
    GASTROENTEROLOGY, 2019, 156 (06) : S638 - S639
  • [42] Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study
    Chaparro, Maria
    Baston-Rey, Iria
    Fernandez-Salgado, Estela
    Gonzalez Garcia, Javier
    Ramos, Laura
    Diz-Lois Palomares, Maria Teresa
    Arguelles-Arias, Federico
    Iglesias Flores, Eva
    Cabello, Mercedes
    Rubio Iturria, Saioa
    Nunez Ortiz, Andrea
    Charro, Mara
    Ginard, Daniel
    Duenas Sadornil, Carmen
    Merino Ochoa, Olga
    Busquets, David
    Iyo, Eduardo
    Gutierrez Casbas, Ana
    Ramirez de la Piscina, Patricia
    Maia Bosca-Watts, Marta
    Arroyo, Maite
    Jose Garcia, Maria
    Hinojosa, Esther
    Gordillo, Jordi
    Martinez Montiel, Pilar
    Velayos Jimenez, Benito
    Quilez Ivorra, Cristina
    Vazquez Moron, Juan Maria
    Maria Huguet, Jose
    Gonzalez-Lama, Yago
    Munagorri Santos, Ana Isabel
    Manuel Amo, Victor
    Dolores Martin-Arranz, Maria
    Bermejo, Fernando
    Martinez Cadilla, Jesus
    Rubin de Celix, Cristina
    Fradejas Salazar, Paola
    Lopez San Roman, Antonio
    Jimenez, Nuria
    Garcia Lopez, Santiago
    Figuerola, Anna
    Jimenez, Itxaso
    Martinez Cerezo, Francisco Jose
    Taxonera, Carlos
    Varela, Pilar
    de Francisco, Ruth
    Monfort, David
    Molina Arriero, Gema
    Hernandez Camba, Alejandro
    Javier Garcia-Alonso, Francisco
    INFLAMMATORY BOWEL DISEASES, 2022, 28 (11) : 1725 - 1736
  • [43] Comparison of Real-World Treatment Outcomes With Vedolizumab Versus Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease
    Patel, Haridarshan
    Latremouille-Viau, Dominick
    Burne, Rebecca
    Shi, Sherry
    Adsul, Shashi
    CROHNS & COLITIS 360, 2019, 1 (02)
  • [44] Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naive Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study
    Bokemeyer, Bernd
    Plachta-Danielzik, Sandra
    di Giuseppe, Romina
    Efken, Philipp
    Mohl, Wolfgang
    Hoffstadt, Martin
    Krause, Thomas
    Schweitzer, Axel
    Schnoy, Elisabeth
    Atreya, Raja
    Teich, Niels
    Trentmann, Leo
    Ehehalt, Robert
    Hartmann, Petra
    Schreiber, Stefan
    INFLAMMATORY BOWEL DISEASES, 2024, 30 (05) : 746 - 756
  • [45] Efficacy and safety of ustekinumab in Crohn's disease: A real-world study from Australia
    Ramaswamy, P. Kakkadasam
    Moattar, H.
    Sawyer, E.
    Edwards, J.
    Shukla, D.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S564 - S565
  • [46] Early real-world effectiveness of ustekinumab for Crohn's disease
    Harris, Richard James
    McDonnell, Martin
    Young, David
    Bettey, Marion
    Downey, Louise
    Pigott, Lucinda
    Felwick, Richard
    Gwiggner, Markus
    Cummings, J. R. Fraser
    FRONTLINE GASTROENTEROLOGY, 2020, 11 (02) : 111 - 116
  • [47] THE REAL-WORLD EFFECTIVENESS OF USTEKINUMAB IN THE TREATMENT OF CROHN'S DISEASE
    Johnson, Amanda M.
    Barsky, Maria
    Ahmed, Waseem
    Zullow, Samantha
    Galati, Jonathan S.
    Jairath, Vipul
    Narula, Neeraj
    Peerani, Farhad
    Click, Benjamin H.
    Coburn, Elliot
    Dang, Thucnhi T.
    Gold, Stephanie
    Agrawal, Manasi
    Garg, Rajat
    Aggarwal, Manik
    Mohammad, Danah
    Halloran, Brendan P.
    Kochhar, Gursimran
    Todorowski, Hannah
    Mohy-Ud-Din, Nabeeha
    Izanec, James L.
    Teeple, Amanda M.
    Gasink, Christopher
    Muser, Erik
    Ding, Zhijie
    Swaminath, Arun
    Lakhani, Komal
    Hogan, Daniel
    Datta, Samit
    Ungaro, Ryan C.
    Singh, Siddharth
    Boland, Brigid
    Bohm, Matthew
    Fischer, Monika
    Sashi, Sagi
    Afzali, Anita
    Ullman, Thomas
    Lawlor, Garrett
    Baumgart, Daniel C.
    Chang, Shannon
    Hudesman, David
    Lukin, Dana J.
    Scherl, Ellen J.
    Colombel, Jean Frederic
    Sands, Bruce E.
    Siegel, Corey A.
    Regueiro, Miguel D.
    Sandborn, William J.
    Bruining, David H.
    Kane, Sunanda V.
    GASTROENTEROLOGY, 2021, 160 (06) : S121 - S121
  • [48] Effectiveness and safety of tocilizumab in monotherapy in biologic-naive and non-naive patients with rheumatoid arthritis in a real-world setting
    Marsal Barril, Sara
    Auxiliadora Martin-Martinez, Ma
    Javier Blanco-Garcia, Francisco
    Fernandez-Nebro, Antonio
    Garcia de Vicuna, Rosario
    Tornero-Molina, Jesus
    Sanchez-Alonso, Fernando
    Novella-Navarro, Marta
    Escudero-Contreras, Alejandro
    Jose Alegre-Sancho, Juan
    Urruticoechea-Arana, Ana
    Sagrario Bustabad-Reyes, Maria
    Trenor-Larraz, Pilar
    Perez-Sandoval, Trinidad
    Isabel Tevar-Sanchez, Maria
    Sanchez-Costa, Jesus T.
    Raya-Alvarez, Enrique
    REUMATOLOGIA CLINICA, 2022, 18 (10): : 567 - 573
  • [49] Patients with Crohn's disease treated with ustekinumab vs. vedolizumab in real-world settings
    Chiorean, M.
    Jiang, J.
    Candela, N.
    Chen, G.
    Romdhani, H.
    Latremouille-Viau, D.
    Shi, S.
    Bungay, R.
    Fan, T.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S630 - S630
  • [50] Real-world effectiveness and safety of ustekinumab for the treatment of refractory Crohn's disease: The Scottish ustekinumab cohort
    Plevris, N.
    Robertson, A.
    Fulforth, J.
    Hall, R.
    Campbell, I.
    Kane, C.
    Veryan, J.
    Lam, W.
    Saunders, J.
    Jenkinson, P.
    Chuah, C.
    Kelly, C.
    Watts, D.
    Gaya, D.
    Macdonald, J.
    Jafferbhoy, H.
    Seenan, J. P.
    Mowat, C.
    Sutherland, D.
    Naismith, G.
    Bain, G.
    Arnott, I.
    Jones, G.
    Lees, C.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S484 - S484